))
Antibody discovery with LabGenius' James Field
Manage episode 422212455 series 3573130
Content provided by Balderton Capital. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Balderton Capital or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
What do synthetic biology, machine learning and robotics have in common? James Field, CEO and founder of LabGenius, explains how his company is integrating bleeding-edge technologies from across these fields to discover the next-generation therapeutic antibodies. And change the way we approach drug discovery.
Find out more about Labgenius here and follow them on LinkedIn
Chapters
1. Intro (00:00:00)
2. How James’ PhD experience shaped his entrepreneurial journey (00:05:25)
3. Why grants play a crucial role for deeptech startups (00:09:50)
4. LabGenius’ fundraising experience (00:12:35)
5. On growing the team (00:17:55)
6. What does success look like for LabGenius in the next few years (00:21:05)
7. Why now is the moment for synthetic biology (00:21:59)
8. Changing scientific discovery through “silicone scientists” (00:25:00)
9. LabGenius’ relationship with the pharmaceutical industry (00:33:47)
10. Where software companies fit in (00:36:16)
11. LabGenius' ultimate dream (00:39:05)
7 episodes
Share
